Clinical trials
Mutation clinical trials
Below are recruiting mutation clinical trials, each written for real people, not researchers. We’re tracking 739 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07304739RecruitingPhase 2
Furmonertinib plus radiation and chemo for EGFR lung cancer with brain spread
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
Cangzhou, HebeiAges 18–75 - NCT07329257Recruiting
Project PENGUIN: Study of rare brain development disorders
This study looks at rare and ultra-rare conditions that affect brain development. It aims to learn more about what causes these conditions. You may join if you or your child have a diagnosed or suspected neurogenetic disorder.
Columbia, MissouriAges Up to 99 years - NCT07329322RecruitingPhase 2
Drug combo before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
BeijingAges 18–75 - NCT07336732RecruitingPhase 2
New targeted drug with chemo for rare EGFR lung cancer
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
GuangzhouAges 18 years+ - NCT07383506RecruitingPhase 1
Study of a targeted pill for PIK3CA-mutated advanced cancers
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
Scottsdale, ArizonaAges 18 years+ - NCT07348965Recruiting
High-dose furmonertinib for EGFR-mutant lung cancer that spread to the brain lining
This trial tests a new way to give a targeted therapy (furmonertinib) to people with a specific type of lung cancer that has spread to the lining of the brain. It uses a higher, pulsing dose to try to get more medicine into the brain fluid and stop the cancer there.
Guangzhou, GuangdongAges 18–75 - NCT07356544Recruiting
HER2 mutations in advanced non-small cell lung cancer
This study is looking at how common HER2 gene changes are in people with advanced non-small cell lung cancer (NSCLC) and how these changes affect treatment. By joining, you help researchers learn more about personalized care for this type of lung cancer.
Bari, BAAges 18 years+ - NCT07361237RecruitingPhase 1
HJ-004-02 tablet for EGFR-mutated lung cancer
This early-phase trial tests a once-daily tablet (HJ-004-02) for people with a specific type of lung cancer that has an EGFR mutation. It aims to see if the drug is safe and if it can shrink tumors when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07362225Recruiting
MPN Progress Registry: Tracking Symptoms and Progression
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
Chicago, IllinoisAges 18 years+ - NCT07371104RecruitingPhase 1
Study of DWZ2501 in advanced BRCA ovarian cancer on olaparib
This trial compares how the body processes a new formulation of olaparib (DWZ2501) versus the standard version. It is for women with advanced, BRCA-mutated high-grade ovarian cancer who are already on or about to start a stable dose of olaparib 300 mg twice daily.
Seoul, Jongno-guAges 19 years+ - NCT07375316RecruitingPhase 2
Combination therapy for EGFR-mutated lung cancer with lingering ctDNA
This trial tests if adding sacituzumab tirumotecan to osimertinib works better than osimertinib alone for advanced lung cancer that still shows cancer DNA (ctDNA) in the blood after initial osimertinib treatment.
Guangzhou, GuangdongAges 18 years+ - NCT07379476RecruitingPhase 2
Targeted treatment for remaining spots in EGFR lung cancer
This trial tests whether adding targeted radiation or surgery to your regular osimertinib treatment can better control any remaining spots of lung cancer. It is for people with a specific EGFR mutation whose cancer has shrunk but left a few active sites.
Hong KongAges 18 years+ - NCT07392658RecruitingPhase 2
Amivantamab plus chemo for EGFR-mutated lung cancer
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
Roma, Roma (RM)Ages 18–99 - NCT07397728Recruiting
TREX1 gene changes in lupus with skin rashes
This trial tests for a specific gene change (in the TREX1 gene) in people with lupus, especially those who have lupus-related skin rashes. It aims to understand how this gene may affect the disease.
Qina, South ValleyAges 18–60 - NCT01443468Recruiting
Study of Li-Fraumeni syndrome family cancer risk
This study collects medical and genetic information to better understand how often cancer develops in people with Li-Fraumeni syndrome and related family risks. It may help families and doctors plan earlier awareness and follow-up over a person’s lifetime.
Bethesda, MarylandAges Any age - NCT00280202Recruiting
Find lung cancer genetic markers from tissue samples
This study looks for specific genetic markers of lung cancer by testing tissue taken from a lung mass. It may help doctors detect and better understand lung cancer based on genetic clues.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT01532791Recruiting
Study of mitochondrial mutation m.3243A>G in families
This study looks at the natural course of a specific inherited mitochondrial DNA change (m.3243A>G) over time. It may help doctors better understand how this mutation affects health and outcomes, even if no treatment is given.
New York, New YorkAges 4 years+ - NCT01403402Recruiting
Study of congenital muscle disease patients and their families
This trial collects health information from patients with certain inherited (genetic) muscle diseases and from their families. It may help researchers better understand the disease and improve care by learning what symptoms and treatments patients experience over time.
Lakewood, CaliforniaAges Any age - NCT01668186Recruiting
Study of how peroxisome disorders change over time
This study follows people with peroxisome biogenesis disorders (PBD) or closely related enzyme/protein defects to learn how symptoms and health changes over time. It may help researchers better understand the condition and plan future treatments.
Montreal, QuebecAges Any age - NCT01861106RecruitingPhase 2
Bone marrow transplant for people with GATA2 gene changes
This trial tests whether an allogeneic bone marrow (stem cell) transplant can improve outcomes for people with GATA2 gene changes or “MonoMAC” syndrome. It aims to rebuild a healthier immune system in patients who have serious infections and immune cell deficiencies.
Bethesda, MarylandAges 6–70 - NCT02432092Recruiting
Genetic testing for heart muscle disease in children and families
This study looks at genetic (DNA) changes that may cause cardiomyopathy, a disease where the heart muscle is weakened. It may help families understand possible causes and inform future care.
Indianapolis, IndianaAges Any age - NCT02280161Recruiting
Study of inherited cancer gene samples in blood and saliva
This study collects blood and saliva to look for inherited gene changes in people who have been diagnosed with cancer. It may help researchers understand what genetic risks could be involved, which could guide future cancer care.
Los Angeles, CaliforniaAges 18 years+ - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT02302742Recruiting
Registry for triple-negative breast cancer and inherited mutation carriers
This registry studies people with triple-negative breast cancer or inherited “HBOC” gene mutations (like BRCA, PALB2, PTEN, TP53). It collects information to better understand risk, outcomes, and how these cancers behave—helping future research and care.
Hays, KansasAges Any age
Hear when a new Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mutation?
- Yes. Clin2 currently lists 739 recruiting mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.